請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5477
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張國柱 | |
dc.contributor.author | Chih-Hsien Wang | en |
dc.contributor.author | 王植賢 | zh_TW |
dc.date.accessioned | 2021-05-15T18:00:05Z | - |
dc.date.available | 2014-02-25 | |
dc.date.available | 2021-05-15T18:00:05Z | - |
dc.date.copyright | 2014-02-25 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-01-23 | |
dc.identifier.citation | An D, Rodrigues B (2006) Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291:H1489-1506.
Bachmann E, Weber E (1988) Biochemical mechanisms of oxfenicine cardiotoxicity. Pharmacol 36:238–48. Barnea O, Jaron D (1990) A new method for the estimation of the left ventricular pressure-volume area. IEEE Trans Biomed Eng 37:109–111. Bergman G, Atkinson L, Metcalfe J, Jackson N, Jewitt DE (1980) Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenyl glycine)in angina pectoris. Eur Heart J 1:247–253. Beuge JA, Aust SD (1978) Microsomal lipids peroxidation. Methods Enzymol 52:302–310. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625. Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA (2006). Acety-lcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr Biochem 17:73-88. Campbell KB, Ringo JA, Neti C, Alexander JE (1984) Informational analysis of left ventricle/systemic arterial interaction. Ann Biomed Eng 12:209-231. Campbell KB, Ringo JA, Knowlen GG, Kirkpatrick RD, Schmidt SL (1986) Validation of optimal elastance-resistance left ventricle pump models. Am J Physiol 251:H382–H397. Campbell K B, Kirkpatrick R D, Knowlen GG, Ringo JA (1990) Late-systolic pumping properties of the left ventricle. Deviation from elastance-resistance behavior. Circ Res 66: 218-233. Chang KC, Kuo TS (1997) Single beat estimation of the ventricular pumping mechanics in terms of the systolic elastance and resistance. J theor Biol 189:89–95. Chang KC (1998) Theoretical maximum flow of the left ventricle is sensitive to change in ventricular afterload. J theor Biol 194:407–417. Chang KC, Lo HM, Tseng YZ (2002) Systolic elastance and resistance in the regulation of cardiac pumping function in early streptozotocin-diabetic rats. Exp Biol Med 227:251–259. Chang KC, Hsu KL, Tseng CD, Lin YD, Cho Y et al. (2006). Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol 147:944-950. Chang KC, Tseng CD, Lu SC, Liang JT, Wu MS et al. (2010) Effects of acetyl-L-carnitine and oxfenicine on aorta stiffness in diabetic rats. Eur J Clin Invest 40:1002–1010. Del Rio D, Stewart AJ, Pellegrini N (2005) A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovas Dis 15:316–328. Dennis JE, Woods DJ (1987) New Computing Environments. In: Wouk A, Eds. Microcomputers in Large-Scale Computing. Philadelphia: SIAM, p.116–122. Dillmann WH (1980) Diabetes mellitus induces changes in cardiac myosin in the rat. Diabetes 29:579–582. Fernandez E, Pallini R, Gangitano C, Del Fa A, Sangiacomo CO et al. (1989) Effects of L-carnitine, L-acetylcarnitine, and gangliosides on the regeneration of the transected sciatic nerve in rats. Neurol Res 11:57–62. Folden DV, Gupta A, Sharma AC, Li SY, Saari JT et al. (2003) Malondialdehyde inhibits cardiac contractile function in ventricular myocytesvia a p38 mitogen-activated protein kinase-dependent mechanism. Brit J Pharmacol 139:1310–1316. Huijberts MS, Schaper NC, Schalkwijk CG (2008) Advanced glycation end products and diabetic foot disease. Diabetes Metab Res Rev 24 Suppl 1:S19-24. Hunter WC, Janicki JS, Weber KT, Noordergraaf A (1979) A: Flow-pulse response: A new method for the characterization of ventricular mechanics. Am J Physiol 237(Heart Circ Physiol 6):H282-H292. Hunter WC, Janicki JS, Weber KT, Noordergraaf A (1983) Systolic mechanical properties of the left ventricle: effects of volume and contractile state. Circ Res52:319–327. Junod A, Lambert AE, Stauffacher W, Renold AE (1969). Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 48:2129-2139. Kato K, Chapman DC, Rupp H, Lukas A, Dhalla NS (1999) Alternations of heart function and Na+-K+ ATPase activity by etomoxir in diabetic rats. J Appl Physiol 86:812-818 Kolwicz SC Jr, Purohit S, Tian R (2013) Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res 113:603-616. Lee L, Horowitz J, Frenneaux M (2004) Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 25:634–641. Liu J, Head E, Kuratsune H, Cotman CW, Ames BN (2004) Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann NY AcadSci 1033:117–131. Malaguarne M (2012) Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol 28:166–176. Malhotra A, Penpargkul S, Fein FS, Sonnenblick EH, Scheuer J (1981) The effects of streptozotocin-induced diabetes in rats on cardiac contractile proteins. Circ Res 49:1243–1250. Malone JI, Cuthbertson DD, Malone MA, Schocken DD (2006) Cardioprotective effects of carnitine in streptozotocin-induced diabetic rats. Cardiovas Diabetol 5:2. McGarry JD, Mills SE, Long CS, Foster DW (1983) Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase-I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J 214:21–28. Mingorance C, Rodriguez-Rodriguez R, Justo ML, Alvarez de Sotomayor M, Herrera MD (2011) Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. Vasc Health Risk Manag 7:169–176. Neely JP, Morgan HE (1974) Relationship between carbohydrate and lipid metabolism and the energy balance of the heart muscle. Annu Rev Physiol 36:413–459. Paulson DJ, Sanjak M, Shug AL (1992) Carnitine deficiency and the diabetic heart. In: Carter AL (ed). Current Concepts in Carnitine Research. CRC Press, Boca Raton, Florida, 215–230. Penpargkul S, Fein FS, Sonnenblick EH, Scheuer J (1981) Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol 13:303–309. Rakieten N, Rakieten ML, Nadkarni MR (1963). Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep 29:91-98. Rice JJ, Winslow RL, Hunter WC (1999) Comparison of putative cooperative mechanisms in cardiac muscle: length dependence and dynamic responses. Am J Physiol 276(Heart Circ Physiol 45):H1734–H1754. Rodrigues B, Xiang H, McNeill JH (1988) Effect of L-Carnitine Treatment on Lipid Metabolism and Cardiac Performance in Chronically Diabetic Rats. Diabetes 37:1358–64. Rodrigues B, McNeill JH (1992) The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 26:913–992. Rodrigues B, Cam MC, McNeill JH (1995) Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27:169–179. Rodrigues B, Cam MC, McNeill JH (1998) Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180:53–57. Rupp H, Zarain-Herzberg A, Maisch B (2002) The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 27:621–636. Sagawa K (1978) The ventricular pressure-volume diagram revisited. Circ Res 43:677-687 Schalkwijk CG and Stehouwer CD (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 109:143-159. Schinetti ML, Rossini D, Greco R, Bertelli A (1987) Protective action of acetyl-carnitine on NADPH-induced lipid peroxidation of cardiac microsomes. Drugs Exp Clin Res 13: 509–515. Shroff SG, Janicki JS, Weber KT (1983) Left ventricular systolic dynamics in terms of its chamber mechanical properties. Am J Physiol 245(Heart Circ Physiol 14):H110–H124. Shroff SG, Janicki JS, Weber KT (1985) Evidence and quantitation of left ventricular systolic resistance. Am J Physiol 249(Heart Circ Physiol 18):H358-H370 Shroff SG, Motz W (1989) Left ventricular systolic resistance in rats with hypertension and hypertrophy. Am J Physiol 257: H386-H394. Shroff SG, Janicki JS, Weber KT (1992) Mechanical and energetic behavior of the intact left ventricle. In: Fozzard HA, Eds. The Heart and Cardiovascular System, Second Edition. NY: Raven, p129–150 Slatter DA, Paul RG, Murray M, Bailey AJ (1999) Reactions of lipid-derived malondialdehyde with collagen. J Biol Chem 274: 19661–19669. Slatter DA, Bolton CH, Bailey AJ (2000) The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 43:550–557. Stanley WC, Lopaschuk GD, McCormack JG (1997) Regulation of energy substrate metabolism in the diabetic heart. Cardiovasr Res 34:25–33. Stanley WC (2004) Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J Cardiovasc Pharmacol Therapeut 9(Supplement 1):S31–S45. Steiber A, Kerner J, Hoppel CL (2004) Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med 25: 455–473. Stephens TW, Higgins AJ, Cook GA, Harris RA (1985) Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 227:651-660 Suga H (1971) Left ventricular time-varying pressure/volum ratio in systole as an index of myocardial inotropism. Jpn Heart J 12:153-160. Suga H, Sagawa K, Shoukas AA (1973) Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 32:314–322. Sunagawa K, Yamada A, Senda Y, Kikuchi Y, Nakamura M et al. (1980) Estimation of the hydromotive source pressure from ejection beats of the left ventricle. IEEE Trans Biomed Eng 27:299–305. Takeuchi M, Igarashi Y, Tomimoto S, Odake M, Hayashi T et al. (1991) Single beatestimation of the slope of the end-systolic pressure-volume relation in the human left ventricle. Circulation 83:202–212. Tomlinson KC, Gardiner SM, Bennett T (1989) Diabetes mellitus in Brattleboro rats: cardiovascular, fluid, and electrolyte status. Am J Physiol 256(6 Pt 2):R1279-1285. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T (1992) Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 44:103-150. Turcani M, Rupp H (1997) Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 96: 3681–3686. Turcani M, Rupp H (1999) Modification of left ventricular hypertrophy by chronic etomixir treatment. Br J Pharmacol 126:501-507 Turpeinen AK, Kuikka JT, Vanninen E, Yang J, Uusitupa MI (2000) Long-term effect of acetyl-L-carnitine on myocardial 123I-MIBG uptake in patients with diabetes. Clin Auton Res 10:13–16. Vara JJ, Deboer C, Dietz A, Hanka LJ, Sokolski WT (1959). Streptozotocin, a new antibacterial antibiotic. Antibiot Annu 7:230-235. Vitale C, Collins P (2008) Optimization of cardiac metabolism in diabetes mellitus. Curr Pharm Design 14:2537–2550. Weiss JL, Frederiksen JW, Weisfeldt ML (1976) Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest 58:751–760. Wang CH, Wang SS, Ko WJ, Chen YS, Chang CY et al. (2013) Acetyl-L-carnitine and oxfenicine on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar rats. PLOS ONE 8:e69977 Wu MS, Liang JT, Lin YD, Wu ET, TsengYZ et al. (2008) Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes. Brit J Pharmacol 154:758–764. Wu MS, Chang CY, Chang RW, Chang KC (2012) Early return of augmented wave reflection impairs left ventricular relaxation in aged Fisher 344 rats. Exp Gerontol 47:680–686. Young ME, McNulty P, Taegtmeyer H (2002) Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 105:1861–1870. Zarain-Herzberg A, Rupp H (2002) Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs 11:345–356. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5477 | - |
dc.description.abstract | 研究背景:
對於糖尿病所引起的左心室心肌功能病變的治療方式,改變心肌細胞能量來源的代謝方式是其中一種方法。由於脂質代謝佔心肌能量來源的大部分,在這個研究裡,我們以肉鹼 (carnitine) 的衍生物乙醯左旋肉鹼 (acetyl-L-carnitine,ALC) 及羥苯甘胺酸 (oxfenicine,OXF) (一種carnitine palmitoyltransferase-1抑制劑) 來影響脂質進入粒腺體的代謝途徑,治療以鏈佐黴素 (streptozotocin) 所引發的糖尿病Wistar-Kyoto鼠,並利用測量左心室壓力與主動脈血流量以得知心臟的收縮功能與內部阻力,比較兩種不同治療方式對於心臟泵浦功能的影響。 研究方法: 以鏈佐黴素 (55mg/kg) 注入兩個月大Wistar-kyoto大鼠尾靜脈誘發糖尿病,之後分別每天餵與乙醯左旋肉鹼 (1 g/L於飲用水) 或是羥苯甘胺酸 (150 mg/kg經口灌食),治療八週後分別與年紀相同之正常組與糖尿病未治療組作比較。在麻醉開胸後測量左心室壓力與升主動脈之血流,以計算最大收縮彈性 (maximal systolic elastance, Emax) 與理論最大血流 (theoretical maximum flow, Qmax)。生理上,Emax可以反映一個完整心臟的心肌收縮功能 (contractility),而Qmax則是與左心室內部阻力有反比關係。 研究結果: 相較于正常組之Wistar-kyoto大鼠,糖尿病鼠的Emax下降,但Qmax不變,顯示心臟的收縮功能下降。不論是以乙醯左旋肉鹼或是羥苯甘胺酸治療糖尿病鼠,Emax均可以增加,顯示兩者均可以改善因糖尿病所引起的心臟收縮力下降。然而,僅有乙醯左旋肉鹼可以降低心肌細胞的丙二醇(malondialdehyde, MDA) 含量,減少脂質的過氧化產物產生。另一方面,以羥苯甘胺酸治療糖尿病鼠會增加週邊血管總阻力,減少Qmax,顯示在以羥苯甘胺酸治療後,心室內部阻力反而增加。 研究結論: 相對於羥苯甘胺酸,乙醯左旋肉鹼對於因糖尿病所引起的心臟泵浦功能不良的治療結果更為適當。因為乙醯左旋肉鹼不但可以增加心肌的收縮功能 (Emax),且不會增加週邊血管總阻力,不至於增加心臟的內部阻力。 | zh_TW |
dc.description.abstract | Introduction:
In the treatment of patients with diabetes, one objective is an improvement of cardiac metabolism to alleviate the left ventricular (LV function. For this study, we compared the effects of acetyl-L-carnitine (one of the carnitine derivatives) and of oxfenicine (a carnitine palmitoyltransferase-1 inhibitor) on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar rats, with a particular focus on the pressure-flow-volume relationship. Methods: Diabetes was induced by a single tail vein injection of 55 mg kg-1 streptozotocin. The diabetic animals were treated on a daily basis with either acetyl-L-carnitine (1 g L-1 in drinking water) or oxfenicine (150 mg kg-1 by oral gavage) for 8 wk. They were also compared with untreated age-matched diabetic controls. LV pressure and ascending aortic flow signals were recorded to calculate the maximal systolic elastance (Emax) and the theoretical maximum flow (Qmax). Physically, Emax reflects the contractility of the myocardium as an intact heart, whereas Qmax has an inverse relationship with the LV internal resistance. Results: When comparing the diabetic rats with their age-matched controls, the cardiodynamic condition was characterized by a decline in Emax associated with the unaltered Qmax. Acetyl-L-carnitine (but not oxfenicine) had reduced cardiac levels of malondialdehyde in these insulin-deficient animals. However, treating with acetyl-L-carnitine or oxfenicine resulted in an increase in Emax, which suggests that these 2 drugs may protect the contractile status from deteriorating in the diabetic heart. By contrast, Qmax showed a significant fall after administration of oxfenicine, but not with acetyl-L-carnitine. The decrease in Qmax corresponded to an increase in total vascular resistance when treated with oxfenicine. Conclusions: Acetyl-L-carnitine, but not oxfencine, optimizes the integrative nature of cardiac pumping mechanics by preventing the diabetes-induced deterioration in myocardial intrinsic contractility associated with unaltered LV internal resistance. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T18:00:05Z (GMT). No. of bitstreams: 1 ntu-103-D96441003-1.pdf: 1839844 bytes, checksum: b4088bf7f2feb623d928da3d03c6e576 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 誌謝.......................................................i
中文摘要...................................................ii Abstract..................................................iv 目錄......................................................vi 第一章 研究背景..............................................1 1 正常心肌細胞的能量來源是葡萄糖與脂肪酸..........................1 2 糖尿病與心血管疾病..........................................3 2-1 糖尿病的血管病變..........................................3 2-2 糖尿病的心肌病變..........................................4 3 肉鹼棕櫚醯轉移酶-1與肉鹼.....................................7 3-1 乙醯左旋肉鹼.............................................7 3-2 羥苯甘胺酸..............................................9 4 鏈佐黴素引發之第一型(胰島素缺乏)糖尿病模式.....................10 5 研究目的.................................................11 第二章 研究方法.............................................13 1 實驗動物製備..............................................13 2 實驗動物分組..............................................13 2-1 乙醯左旋肉鹼之投藥方式....................................14 2-2 羥苯甘胺酸之投藥方式.....................................15 3 實驗儀器介紹..............................................15 3-1 高傳真壓力感應器.........................................15 3-2 電磁感應血流計..........................................16 4 實驗動物手術流程...........................................17 5 左心室/體重比.............................................18 6 彈性-阻力模型與左心室壓力...................................19 7 左心室收縮末期平衡點.......................................21 8 心臟dP/dtmax、dP/dtmin及左心室等容壓力下降的時間常數τ.........22 9 以硫巴比妥鹽檢測法估計左心室中的丙二醇含量.....................22 10 統計方法................................................24 第三章 研究結果與討論........................................25 1 乙醯左旋肉鹼可以減緩因鏈佐黴素誘發之糖尿病大鼠左心室肥大..........25 2 羥苯甘胺酸會增加鏈佐黴素誘發之糖尿病大鼠之主動脈平均血壓..........27 3 乙醯左旋肉鹼與羥苯甘胺酸均可改善糖尿病鼠的dP/dtmax,但乙醯左旋肉鹼還可以改善dP/dtmin...........................................28 4 彈性-阻力模型的擬合優度.....................................29 5 乙醯左旋肉鹼與羥苯甘胺酸均可改善糖尿病鼠的最大收縮彈性............30 6 羥苯甘胺酸會增加糖尿病鼠週邊血管總阻力並降低理論最大血流量........31 7 週邊血管總阻力增加,理論最大血流量降低,兩者呈現負相關............32 8 乙醯左旋肉鹼可以降低糖尿病鼠心臟之MDA/TBARS含量................33 9 研究討論.................................................34 10 研究成果................................................38 第四章 研究結論.............................................39 第五章 研究特色.............................................40 第六章 研究限制.............................................43 圖次 圖1.......................................................44 圖2.......................................................45 圖3.......................................................46 圖4.......................................................47 圖5.......................................................48 表次 表1 ALC與OXF隊以STZ誘發糖尿病大鼠血糖、體重與左心室重量的影響......49 表2 ALC與OXF隊以STZ誘發糖尿病大鼠血液動力學參數的影響............50 表3 ALC與OXF隊以STZ誘發糖尿病大鼠的心臟功能的影響................51 參考文獻...................................................52 附錄......................................................62 | |
dc.language.iso | zh-TW | |
dc.title | 乙醯左旋肉鹼(Acetyl-L-Carnitine)與羥苯甘胺酸(Oxfenicine)對鏈佐黴素(Streptozotocin)所引發之糖尿病鼠心臟力學之影響 | zh_TW |
dc.title | Effects of Acetyl-L-Carnitine and Oxfenicine on the Cardiac Pumping Mechanics in Streptozotocin-Induced Diabetic Rats | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 柯文哲,虞希禹,陳益祥,王水深,蔡明憲 | |
dc.subject.keyword | 肉鹼棕櫚醯轉移?-1,彈性-阻力模型,dP/dtmax,dP/dtmin,理論最大血流量,硫巴比妥鹽檢測法, | zh_TW |
dc.subject.keyword | Carnitine palmitoyltransferase-1,Elastance-Resistance Model,dP/dtmax,dP/dtmin,Theoretical maximum flow,MDA/TBARS assay, | en |
dc.relation.page | 62 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-01-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 1.8 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。